INSIGHTS INTO THIORIDAZINE FOR ITS ANTI-TUBERCULAR ACTIVITY FROM MOLECULAR DOCKING STUDIES
Keywords:
Thioridazine (TZ), Efflux pumps, Molecular docking, Enzymes, Binding energy, MDR, XDRAbstract
Objective: Thioridazine (TZ) is a drug that has been used for over 35 years as a psychoactive drug, is now potentially utilized in combination with certain anti-TB drugs to cure MDR, XDR and TDR TB. The current study explores the plausible reasons for its anti-tubercular activity through molecular docking procedure.
Methods: Molecular docking were performed by using the molecular modeling software Glide®from the suite of Schrödinger Inc., Molecular docking studies were performed to study the binding affinity of Thioridazine on the active sites of various Mycobacterium tuberculosis enzymes in an effort to increase the understanding of the action of Thioridazine (TZ) as an antitubercular agent. Seventeen enzymes from different mechanisms were docked and the resulting glide scores (G-Scores) were tabulated.
Results: The enzyme CmaA2 - Cyclopropane mycolic acid synthase (PDB id: 1KPI) scored lowest binding energy which means the greater stability of the thioridazine's ability to bind to the receptor. MmaA2 (1TPY), InhA (2NSD) and PknG (2PZI) enzymes of Mycobacterium tuberculosis gave the best G-scores.
Conclusion: The docking study results revealed that Thioridazine may act by more than one possible mechanism to exert anti-tubercular activity against MDR (Multi Drug Resistant), XDR (Extensively Drug Resistant) and TDR (Totally Drug Resistant) -TB.
Â
Downloads
References
Global tuberculosis report; World Health Organization (WHO), Geneva, Switzerland, Retrieved; 2014. p. 8-10.
World Health Organization, Global tuberculosis report, Geneva, Switzerland, Retrieved; 2014. p. 8-10.
Udwadia ZF, Sen T, Pinto LM. Safety and efficacy of Thioridazine as salvage therapy in Indian patients with XDR-TB. Rec Pat Anti-Infect Drug Dis 2011;6(2):88-91.
Diane Ordway, Miguel Viveiros, Clara Leandro, Rosa´rio Bettencourt, Josefina Almeida, Marta Martins, et al. Clinical Concentrations of Thioridazine Kill Intracellular Multidrug-Resistant Mycobacterium tuberculosis. J Antimicrob Chemother 2003;47(3):917–22.
Amaral L, Molnar J. Why and how Thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis. Exp Rev Anti Infect Ther 2012;10:869-73.
Leonard A, Jette EK, Miguel V, Jorge A. Activity of phenothiazines against antibiotic resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as antituberculosis therapy. J Antimicrob Chemother 2001;47:505-11.
Leonard A, Martin J, Stephen H, Udwadia ZF, Soolingen DV. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now. Int J Antimicrob Agents 2010;35:524–6.
Van Ingen J. The broad-spectrum antimycobacterial activities of phenothiazines, in vitro: somewhere in all of this there may be patentable potentials. Rec Pat Anti infect Drug Dis 2011;6:104–9.
Dutta NK, Mazumdar K, Dastidar SG, Karakousis PC, Amaral L. New patentable use of an old neuroleptic compound Thioridazine to combat tuberculosis: a gene regulation perspective. Rec Pat Anti infect Drug Dis 2011;6(2):128-38.
Parvathy NG, Manju P, Mukesh M, Leena T. Design, Synthesis and Molecular docking studies of Benzothiazole derivatives as Anti microbial agents. IJPPS 2013;5(2):101-6.
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A new approach for rapid, accurate docking and scoring. J Med Chem 2004;47(7):1739-49.
Daniel B, Zhen L, James CS, Michael SG. Mycolic acid cyclopropanation is essential for viability, Drug Resistance, and Cell Wall Integrity of Mycobacterium tuberculosis. Chem Biol 2009;16:499–509.
Michael SG. The mmaA2 Gene of Mycobacterium tuberculosis Encodes the Distal Cyclopropane Synthase of the α-Mycolic Acid. J Biol Chem 2003;278(10):7844–9.
Xin H, Akram A, Paul R, Montellano O. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem 2007;15(21):6649–58.
Nicole S, Srinivas H, Gabriele K, Philipp M, Rajesh J, Fritz W, et al. Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. PNAS 2007;104(29):12151-6.
Rajesh PK, Rohini K, Srikumar PS. Anti-tuberculosis drugs against Mycobacterium tuberculosis PKnB and mutants’ l33d/ d76a–A comparative docking study. IJPPS 2014;6(1):662-4.
Erdemli SB, Gupta R, Bishai WR, Bianchat MA. Targeting the cell wall of Mycobacterium tuberculosis: Structure and mechanism of L, D-transpeptidase 2. Struc 2012;20(12):2103-15.
Nordqvist A, Nilsson MT, Lagerlund O, Muthas D, Gising J, Yahiaoui S, et al. Synthesis, Biological evaluation and x-ray crystallographic studies of imidazo (1, 2-A) pyridine-based Mycobacterium Tuberculosis Glutamine Synthetase Inhibitors. Med Chem Comm 2012;3:620.
Huang CC, Smith CV, Glickman MS, Jacobs W Jr, Sacchettini JC. Crystal structures of Mycolic acid Cyclopropane synthases from Mycobacterium tuberculosis. J Biol Chem 2002;277(13):11559-69.
Liliana R, Cristina V, Rebeca B, Miguel V, José AA. Role of the mmr efflux pump in drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2013;57(2):751–7.
William BP, Mary CL, Vincent E. Identification and characterization of a unique adenosine kinase from Mycobacterium tuberculosis. J Bact 2003;183(22):6548-55.
Pan F, Jackson M, Ma Y, McNeil MR. Cell wall core galactofuran synthesis is essential for growth of mycobacteria. J Bact 2001;183(13):3991-8.
Musayev F, Sachdeva S, Scarsdale JN, Reynolds KA, Wright HT. Crystal structure of a substrate complex of Mycobacterium tuberculosis-ketoacyl-acyl carrier protein synthase III (FabH) with lauroyl-coenzyme A. J Mol Biol 2005;346(5):1313-21.
Qiao C, Gupte A, Bosho HI, Wilson DJ, Bennett EM, Somu RV, et al. O-[(N-Acyl) sulfamoyl] adenosines as antitubercular agents that inhibit mbta: an adenylation enzyme required for siderophore biosynthesis of the mycobactins. J Med Chem 2007;50(24):6080-94.
Kremer L, Nampoothiri KM, Lesjean S, Dover LG, Graham S, Betts JC, et al. Biochemical characterization of acyl carrier protein (AcpM) and Malonyl-CoA: AcpM Transacylase (mtFabD), Two Major Components of Mycobacterium tuberculosis fatty acid synthase II. J Biol Chem 2001;276:27967-74.
Sampathkumar P, Turley S, Ulmer JE, Rhie HG, Sibley CH, Hol WG. Structure of Mycobacterium tuberculosis flavin dependant Thymidylate Synthase (MtbThyX) at 2.0 A0resolution. J Mol Biol 2003;352(5):1091-104.
Sierra LD, Munier LH, Gliies AM, Barzu O, Delarue M. X-ray Crystal Structure of TMP Kinase from Mycobacterium tuberculosis complexed with TMP at 1.95A0resolution. J Mol Biol 2001;311(1):87-100.
Vadim M, Giulia M, Katarina M, Ute M. Benzothiazinones Kill Mycobacterium tuberculosis by blocking arabinan synthesis. Sci 2009;324(5928):801–4.
Belanger AE, Besra GS, Ford ME, Mikusova K, Belisle JT, Brennan PJ, et al. The embA, B genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci 1996;93(21):11919-24.